ARS Pharmaceuticals shares rise 10.18% in intraday trading following disclosure of its biotherapy company status and FDA-approved needle-free epinephrine product neffy.

ARS Pharmaceuticals surged 10.18% in intraday trading, as the company, which specializes in commercializing neffy—the first needle-free epinephrine product approved by the FDA and the European Commission for treating Type I hypersensitivity reactions including anaphylaxis, disclosed its 2026 annual report.